Brian Skaug is a Rheumatology/Immunology physician affiliated with The University of Texas Health Science Center at Houston. OpenAlex indexes 47 publications with 3,379 citations (h-index 18).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6410 Fannin St
Suite 450
Houston, TX 770303000
Telephone
713-486-3100Provider last certified this registry record 24 Mar 2024.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20255 payments
- Janssen Biotech, Inc.Program year20251 payment
- UCB, Inc.Program year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
38.2%Corticosteroid29%Prednisone100%Part D≥20 patientsProton pump inhibitor9.3%Omeprazole54%Pantoprazole Sodium46%Part D<11 patientsAntiparasitic
20.1%Antimalarial20.1%Hydroxychloroquine Sulfate100%Part D≥12 patientsNervous system
15.8%Opioid Agonist10.4%Tramadol Hcl100%Part D<11 patientsSNRI5.4%Duloxetine Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2022–2026 per NIH RePORTER. The latest:
- Pathogenic effects of the DNASE1L3 R206C variant in systemic sclerosis
University of Texas Hlth Sci Ctr Houston
FY2026$164,160K08AR081402 - Pulmonary arterial hypertension susceptibility in systemic sclerosis patients with the DNASE1L3 R206C variant
University of Texas Hlth Sci Ctr Houston
FY2026$156,000R03AR086931 - Pathogenic effects of the DNASE1L3 R206C variant in systemic sclerosis
University of Texas Hlth Sci Ctr Houston
FY2025$164,160K08AR081402
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Frank Arnett, MD
The University of Texas Health Science Center at Houston
Ali Marian, MD
The University of Texas Health Science Center at Houston
Anjail Sharrief, MD
The University of Texas Health Science Center at Houston
Heidi Russell, MD
The University of Texas Health Science Center at Houston
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”